Antiviral therapy | Geno-type | Response guided therapy | Definition of "undetectable" HCV RNA result to assess SVR (IU/mL) | |||
---|---|---|---|---|---|---|
On-therapy decision? | Responder time point (weeks) | HCV RNA result considered "undetectable" † | Treatment duration (weeks) | |||
PEGα/RBV | 1-6 | YES | 4 or 12 | week 4, (RVR) <50 IU/mL or week 12, (partial responder) 2 log10 drop | 24, 48, or 72 | < 50 |
PEGα/RBV +TVR | 1 | YES | 4 and 12 | TND, both RGT timepoints | 24 or 48 | < 25 |
PEGα/RBV +BOC | 1 | YES | 8 and 16** | TND, both RGT timepoints | 28, 36, or 48 | < 25 |
PEGα/RBV +SIM | 1 | YES* | 12 | < 25 IU/mL | 24 or 48 | < 25 |
PEGα/RBV +SOF | 1 | N/A | N/A | N/A | 12 | < 25 |
SOF/RBV | 2, 3 | N/A | N/A | N/A | 12 or 24 | < 25 |